Editas Medicine to Restructure, Cut 20% of Staff
Editas Medicine said Monday that it is undertaking a portfolio reprioritization and research-and-development realignment, which will include cutting 20% of its The company said its R&D efforts would narrow, focusing on hemoglobinopathies and in-vivo discovery, allowing it to…
Read More